LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer
Author:
Funder
China Scholarship Council
Deutsche Forschungsgemeinschaft
Publisher
Elsevier BV
Subject
Multidisciplinary
Reference36 articles.
1. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial;Hu;Lancet Oncol,2015
2. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial;Thatcher;Lancet Oncol,2015
3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013
4. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
5. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line;Lee;Biochem Pharmacol,2010
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches;Environmental Research;2024-01
2. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer;Drug Resistance Updates;2023-11
3. Pancreatic Ductal Adenocarcinoma: The Characteristics of Contrast-Enhanced Ultrasound Are Correlated with the Hypoxic Microenvironment;Diagnostics;2023-10-20
4. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance;Journal of Experimental & Clinical Cancer Research;2023-08-09
5. Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy;Pharmaceutics;2023-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3